

	Rinaudo, JoAnn; National Cancer Institute Schinazi, Raymond F.; Emory University, Yerkes National Primate Research Center SEEGER, Christoph; Fox Chase Cancer Research Shetty, Kirti; Sibley Memorial Hospital, Division of Gastroenterology & Hepatology Tavis, John; St. Louis University School of Medicine, Department of Molecular Microbiology and Immunology Zoulim, Fabien; INSERM, U871
Keywords:	hepatitis B, research, cure, therapeutics

Author Manuscript

SCHOLARONE™
Manuscripts

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of record](#). Please cite this article as [doi:10.1002/hep.29509](https://doi.org/10.1002/hep.29509).

TITLE: A Research Agenda for Curing Chronic Hepatitis B Virus Infection

Harvey Alter MD, Clinical Center, National Institutes of Health, Bethesda, MD
Timothy M. Block, PhD, Hepatitis B Foundation and Baruch S Blumberg Institute, Doylestown, PA
Nathaniel Brown, MD, Hepatitis B Foundation and Baruch S Blumberg Institute, Doylestown, PA
Alan Brownstein, MPH, Hepatitis B Foundation and Baruch S Blumberg Institute, Doylestown, PA
Carol Brosgart, MD, U. California San Francisco School of Medicine and U. California at Berkeley School of Public Health, National Viral Hepatitis Roundtable
Kyong-Mi Chang, MD, University of Pennsylvania School of Medicine and the Philadelphia Veterans Hospital, Philadelphia, PA
Pei-Jer Chen, MD, PhD, National Taiwan University, Taipei, Taiwan
Francis V. Chisari MD, Scripps Institute, La Jolla, CA
Chari Cohen, PhD, Hepatitis B Foundation and Baruch S Blumberg Institute, Doylestown, PA
Hashem El-Serag, MD, Baylor College of Medicine, Houston, TX
Jordan Feld, MD, Toronto General Hospital, Toronto, Canada
Robert Gish, MD, Stanford University Medical Center, Palo Alto, CA and Hepatitis B Foundation, Doylestown, PA
Jeffrey Glenn, MD, PhD, Stanford University School of Medicine, Palo Alto, CA
Tim Greten, MD, National Cancer Institute, NIH, Bethesda, MD
Haitao Guo, PhD, Indiana University School of Medicine, Indianapolis, IN
Juo-Tao Guo, MD, Baruch S Blumberg Institute, Doylestown, PA
Yujin Hoshida, MD, Mt. Sinai School of Medicine, New York, NY
Jianming Hu, MD, PhD, Pennsylvania State University College of Medicine, Hershey, PA
Kris V. Kowdley, MD, Swedish Medical Center, Seattle, WA
Wenhui Li, PhD, National Institute of Biological Sciences, Beijing, China
Jake Liang, MD, National Institute of Diabetes, Digestive and Kidney Diseases, NIH, Bethesda, MD
Stephen Locarnini, MD, PhD, Victorian Infectious Diseases Laboratories, Melbourne, Australia
Anna S. Lok, MD, University of Michigan School of Medicine, Ann Arbor, MI
William Mason, PhD, Fox Chase Cancer Center, Philadelphia, PA
Brian McMahon, MD, Alaska Native Medical Center, Anchorage, AK
Anand Mehta, D. Phil., Medical University of South Carolina, Charleston, SC
Robert Perrillo, MD, Baylor University Medical Center, Dallas, TX
Peter Revill, PhD, Victorian Infectious Diseases Laboratories, Melbourne, Australia
Charles M. Rice, MD, PhD, Rockefeller University, New York, NY
JoAnn Rinaudo, PhD, National Cancer Institute, NIH, Bethesda, MD
Raymond Schinazi, PhD, Emory University, Atlanta, GA
Christoph Seeger, PhD, Fox Chase Cancer Center, Philadelphia, PA
Kirty Shetty, MD, Johns Hopkins University, Baltimore, MD
John Tavis, PhD, St. Louis School of Medicine, St Louis, MO
Fabien Zoulim MD, PhD, Lyon University, Lyon, France

By (listed alphabetically):

Harvey Alter, Timothy Block, Nathaniel Brown, Alan Brownstein, Carol Brosgart, Kyong-Mi Chang, Pei-Jer Chen, Francis V. Chisari, Chari Cohen, Hashem El-Serag, Jordan Feld, Robert Gish, Jeffrey Glenn, Tim Greten, Haitao Guo, Ju-Tao Guo, Yujin Hoshida, Jianming Hu, Kris V. Kowdley, Wenhui Li, Jake Liang, Stephan Locarnini, Anna S. Lok, William Mason, Brian McMahon, Anand Mehta, Robert Perrillo, Peter Revill, Charles M. Rice, JoAnn Rinaudo, Raymond Schinazi, Christoph Seeger, Kirty Shetty, John Tavis and Fabien Zoulim

There is a growing interest in discovery and development of new therapeutics that will cure chronic hepatitis B virus (HBV) infection, due to the recent establishment of new cell culture-based and small animal-based models. These new systems create unprecedented opportunities to study the entire viral life cycle and to search for vulnerabilities that can be exploited for curative purposes. Here we propose a scientific pathway that we believe will lead to the development of curative therapies for chronic HBV infection and its associated diseases.

HBV is an hepatotropic, non-cytopathic, partially double-stranded DNA virus that replicates by reverse transcription of a greater-than-genome-length RNA and causes acute and chronic necro-inflammatory liver disease (hepatitis), cirrhosis of the liver, liver failure, death and hepatocellular carcinoma.^(1, 2) Approximately 2 billion people alive today have been infected by HBV and have residual virus in their liver, 250 million of whom are currently chronically-infected with HBsAg+.^(3, 4) Antiviral drugs that suppress viral replication and retard disease progression are available; however, treatment is generally not curative, is life-long, expensive and limited by the extent to which it reduces the risk of death due to liver disease. A highly effective protective vaccine is available, leading the World Health Organization and the National Academies of Science, Engineering and Medicine to recently declare that elimination of HBV is possible if a curative therapy can be developed to supplement the protective effect of the vaccine.^(3, 5, 6) This document introduces the challenge and presents a roadmap for the discovery of a cure.

Development of a cure for any viral infection requires a sufficiently deep understanding of the virus life cycle and its interaction with the host to identify vulnerabilities that can be exploited to eradicate it from infected cells. The key word here is eradicate. In general, these viral mediated steps include entry, uncoating, establishment and maintenance of a transcriptional template in the nucleus (cccDNA), transcription, translation, replication, assembly, transport and release and nucleus reentry of capsid encoated viral particles. Eradication also requires engagement of the host immune response to control viral spread from any residual infected cells and to counteract any evasive strategies deployed by the virus to defeat the host response and assist in clearance of virally infected cells.

Despite its discovery 50 years ago, most steps in the HBV life cycle and the nature of its interaction with its host are only partially understood because the experimental systems required for such experiments have not been available.⁽⁷⁾ Furthermore, despite the ability of currently available direct acting antiviral drugs to suppress HBV DNA replication, they are rarely curative because they do not prevent the establishment or maintenance of the long-lived HBV cccDNA transcriptional template--the stable nuclear form of the viral genome, which must be eliminated or permanently silenced to achieve a durable HBV cure.⁽⁸⁾

Luckily, experimental systems that permit detailed analysis of cccDNA biogenesis, homeostasis and decay, and all other steps in the viral life cycle were recently developed.⁽⁹⁾ Thus, we are now on the threshold of a period of exploration that, if focused on eliminating the cccDNA transcriptional template of the virus, could lead to a cure of chronic HBV infection, once and for all.

We encourage the scientific community to focus on research leading to discovery of a cure for chronic HBV infection based on these principles, as summarized here and highlighted as illustrations in Fig. 1:

- The surest way to cure HBV is to eliminate or permanently silence its cccDNA.
- The most important impediment to this achievement is our limited understanding of the fundamental molecular mechanisms that control cccDNA biogenesis, homeostasis and decay.
- Understanding these mysteries is now within reach, thanks to recent technological advances that enable definition of these mechanisms.
- Vulnerabilities in the cccDNA “life cycle” that are discovered in the course of these studies can be exploited to develop small molecule and other molecular strategies to eradicate or permanently silence the cccDNA.
- Because these studies will explore the unknown, the outcome, like all great adventures, cannot be predicted. Thus, we suggest that in addition to approaches that directly target cccDNA, independent approaches that target other vulnerabilities in the viral life cycle and either indirectly repress HBV cccDNA or safely establish a curative antiviral immune response, be pursued in parallel.
- Such projects could include genetic approaches to cccDNA mutagenesis (e.g. CRISPR/Cas9), epigenetic modification, or other strategies that can suppress cccDNA transcription (e.g. HBV-targeted antisense and siRNA, HBx-inhibition, etc.) or to prevent its recycling (e.g. capsid inhibitors).

Of course, a vigorous basic and translational research effort to better define the nature of the immune response to HBV in chronically infected patients is also essential. Ideally, the antibody response would be examined at the single B cell level to reveal the extent to which neutralizing antibodies are produced by chronically infected patients and to predict whether patients who are “cured” of HBV by direct acting antivirals will require active immunization to prevent intrahepatic viral spread from any infected cells that remain after treatment, and to protect them from future exposure.

Similarly, the functional and phenotypic characteristics of the HBV-specific T cell response must be studied before, during and after curative treatment to determine the extent to which it contributes to the durability or the failure of a given therapeutic strategy. In addition, immune-based strategies that induce T cell-mediated selective elimination of HBV-infected cells, antibody-mediated delivery of antiviral effector molecules to infected cells, T cell checkpoint inhibition, CAR-T cell infusion, among others, should be explored.

These studies should be iterative, where results from the clinical work guide the laboratory work, and vice versa. In this way, the immunobiology, number of infected cells, and other clinical parameters of chronic hepatitis B as a function of medical intervention, can be followed.

We also note that hepatocellular carcinoma (HCC) can be a consequence of chronic hepatitis B. Therefore, to comprehensively address the problems associated with chronic viral hepatitis B, an improved understanding of the molecular basis of HCC to guide early detection and

treatment is vital. Clinical collaborative networks should also be reinforced and expanded to allow for evaluation of new early detection strategies of HCC and therapeutics of HCC and HBV.

It is also important to note that any intervention that directly or indirectly activates the cytotoxic T cell response to HBV could kill all the infected hepatocytes. This would be good if only a few hepatocytes in a given patient are infected and the functional hepatic reserve in that patient is robust. On the other hand, it could be fatal, inducing an acute on chronic liver disease event (ACLD), if many hepatocytes are infected and hepatic reserve is tenuous. Thus, if the cytotoxic T cell response is activated by any therapeutic intervention, it must be in a “Goldilocks zone” where it kills just enough hepatocytes at just the right rate to clear the infection without either triggering acute hepatic insufficiency or worsening the underlying chronic liver disease. It is imperative, therefore, to do these studies if we hope to predict how infected patients will respond immunologically to curative therapy before treatment begins, keeping in mind that the physician’s first responsibility is “*primum non nocere*,” first, do no harm.

A recent review article from Revill et al (2016) specified broad goals for HBV research and has since led to the establishment of an international coalition of scientists, clinicians and stakeholders, committed to the elimination of hepatitis B virus, (ICE-HBV) (<http://ice-hbv.org/>).⁽¹⁰⁾ Our intention is to support and build upon their report and effort by adding detail to create a roadmap for policy makers from government and other funding institutions, and for planning long-term research.

A cure for hepatitis B is also likely to greatly reduce morbidity and mortality associated with hepatitis delta (HBD) virus infection, end-stage liver disease and HCC, although it is appreciated that these clinical problems deserve a specific research agenda of their own.

It is clearly important to explore multiple viral gene products and life cycle steps for intervention opportunities. To date, of all the candidate approaches considered, elimination of HBV cccDNA is most likely to produce a durable cure of chronic HBV infection, after a finite course of antiviral therapy. The extent to which this can be achieved with drugs, biologicals, genetic manipulations, immunomodulation, etc., is the major question to be answered. While transcriptional silencing of cccDNA may be easier to achieve than physical cccDNA elimination, it would probably require lifelong treatment to produce lifelong effects unless it triggers some unpredictable durable downstream effect like immune-mediated destruction or non-cytolytic elimination of cccDNA from the infected cells. Thus, a vigorous, comprehensive, adequately funded, research effort, involving multiple, complementary approaches must be taken, with the results being shared, in the public domain, as quickly as possible.

Luckily, experimental systems that permit detailed analysis of the cccDNA and other steps in the viral life cycle are now available to the scientific community for these challenges. In our opinion, a concerted discovery effort that is both encouraged and enabled by governmental and nongovernmental funding agencies can make a huge difference in the lives of hundreds of millions of people worldwide. Let’s not let this chance to do so much good slip away.

ACKNOWLEDGEMENTS

The Hepatitis B Foundation, a non-profit organization, initiated the dialogue that led to this manuscript by asking about research priorities, and coordinating communication between the

authors. Theresa Weizman, Ph.D. and Judith Marchand are thanked for help in manuscript preparation.

CONTRIBUTORS

The first draft was written by Timothy Block, with help from Frank Chisari. All authors read and offered comment.

DECLARATION OF INTERESTS

Timothy Block is President of The Hepatitis B Foundation and is on The Boards of Directors of Contravir Pharma and Glycotest, and owns stock in Arbutus Biopharma. These organizations have interests in hepatitis B and liver cancer. His research is supported by the US National Institutes of Health.

Frank Chisari is Emeritus Professor of Virology and Immunology at the Scripps Research Institute, and a consultant for Gilead Sciences.

FIGURE LEGEND

Hepatitis B virus (HBV) life cycle, emphasizing opportunities to suppress viral cccDNA and restore immune control. Host and viral functions that could be exploited for therapeutic purposes are illustrated, beginning with binding of the virus to the NTCP receptor on hepatocytes(1), followed by translocation of the nucleocapsid to the nucleus and formation of cccDNA (2) and synthesis steps (3), (4), leading to either egress (6) of newly formed virions or return of nucleo-capsids to the nucleus (7). Opportunities for cccDNA suppression and immune control are categorized as either acting upon the viral gene products (white boxed text) or acting upon host innate and adaptive immune systems (green boxed text), noting that in many cases these different pathways overlap. Humoral responses are also indicated (Abs, Y). Orange, red brown circles (Small, SHBs, Medium, MHBs, Large, LHBs, respectively); yellow triangle (core protein), blue circle (pol), "X" (x protein), red semi circles, cccDNA and black line, HBV 3.2 kb and sub genomic HBV RNA; 22 nM spheres, rods, and 42 nM virions are also illustrated. The examples of virus life cycle steps and immune modulators are representative and not comprehensive. TLR3 is shown since it is present in hepatocytes, but other TLR receptors may also be exploited therapeutically.

REFERENCES

1. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. *Annu Rev Immunol* 1995;13:29-60.
2. McMahon BJ. Natural history of chronic hepatitis B. *Clin Liver Dis* 2010;14:381-396.
3. Buckley G, Strom, B. *Eliminating the public health problem of hepatitis B and C in the United States: Phase one report*. National Academies Press 2016.
4. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. *Vaccine* 2012;30:2212-2219.
5. Combating hepatitis B, a brief from the World Health Organization; 2016.
6. Ryerson ABE, Christie R.; Altekruze, Sean F.; Ward, John W.; Jemal, Ahmedin; Sherman, Recinda L.; Henley, S. Jane; Holtzman, Deborah; Lake, Andrew; Noone, Anne-

Michelle; Anderson, Robert N.; Ma, Jiemin; Ly, Kathleen N.; Cronin, Kathleen A.; Penberthy, Lynne; and Kohler, Betsy A. Annual Report to the Nation on the Status of Cancer, 1975-2012, Featuring the Increasing Incidence of Liver Cancer. Public Health Resources 2016:Paper 468.

7. Block TM, Alter HJ, London WT, Bray M. A historical perspective on the discovery and elucidation of the hepatitis B virus. *Antiviral Research* 2016;131:109-123.


8. Seeger C, Mason WS. Molecular biology of hepatitis B virus infection. *Virology* 2015;479-480:672-686.

9. Liang TJ, Block TM, McMahon BJ, Ghany MG, Urban S, Guo JT, Locarnini S, et al. Present and future therapies of hepatitis B: From discovery to cure. *Hepatology* 2015;62:1893-1908.

10. Revill P, Testoni B, Locarnini S, Zoulim F. Global strategies are required to cure and eliminate HBV infection. *Nat Rev Gastroenterol Hepatol* 2016;13:239-248.

Author Manuscript


Figure 1



Hepatitis B virus (HBV) life cycle, emphasizing opportunities to suppress viral cccDNA and restore immune control. Illustrated, is an HBV infected hepatocyte, beginning with binding of the virus to the NTCP receptor (1), followed by translocation of the nucleocapsid to the nucleus and formation of cccDNA (2) and synthesis steps (3), (4), leading to either egress (6) of newly formed virions or return of nucleocapsids to the nucleus (7). Opportunities for cccDNA suppression and immune control are categorized as either acting upon the viral gene products (white boxed text) or acting upon host innate and adaptive immune systems (green boxed text), noting that in many cases these different pathways overlap. Humoral responses are also indicated (Abs, Y). Orange, red brown circles (Small, SHBs, Medium, MHBs, Large, LHBs, respectively); yellow triangle (core protein), blue circle (pol), "X" (x protein), red semi circles, cccDNA and black line, HBV 3.2 kb and sub genomic HBV RNA; 22 nM spheres, rods, and 42 nM virions are also illustrated. The examples of virus life cycle steps and immune modulators are representative and not comprehensive.

AU

Figure 1



225x141mm (300 x 300 DPI)

Author M